Genotype-Guided VRET: Personalizing Exposure Therapy Through Serotonin Transporter Profiling

Schrammen et al. (2025) revealed that patients with low-expression 5-HTTLPR genotypes respond poorly to standardized VRET. This idea proposes a closed-loop system where genetic screening pre-treatment informs VRET protocols. Patients with low-expression genotypes receive enhanced multimodal exposure (e.g., haptic feedback + olfactory cues) and adaptive difficulty algorithms, while high-expression responders use conventional protocols. Unlike Petersen et al.'s static biofeedback (2024), this system uses genetic data to pre-emptively personalize therapy, reducing dropout rates. This bridges precision medicine and VRET—a leap from Demir & Köskün’s (2023) "one-size-fits-all" efficacy claims.

References:

1. Efficacy of Virtual Reality Exposure Therapy in the Treatment of Specific Phobias: A Systematic Review. M. Demir, Tolga Köskün (2023). Psikiyatride Guncel Yaklasimlar.
2. Usability Analysis of a Virtual Reality Exposure Therapy Serious Game for Blood Phobia Treatment: Phobos. João Petersen, Vítor Carvalho, J. T. Oliveira, Eva Oliveira (2024). Electronics.
3. Therapygenetics: Serotonin transporter gene polymorphism (5-HTTLPR) is associated with behavioral treatment response to virtual exposure therapy in patients with spider phobia. Elisabeth Schrammen, Chiara Hilbrich, J. Böhnlein, Kati Roesmann, B. Gathmann, M. J. Herrmann, M. Junghöfer, H. Schwarzmeier, F. Seeger, N. Siminski, T. Straube, H. Weber, U. Lueken, U. Dannlowski, Katharina Domschke, Miriam A. Schiele, E. Leehr (2025). European Neuropsychopharmacology.